NEW YORK, April 9 (GenomeWeb News) - Activx Biosciences announced this week that it will apply its activity proteomics technology to characterize the activities of compounds for Foster City, Calif.-based Gilead Sciences.
Activx has similar deals already with Pfizer and Kyorin Pharmaceuticals.
Financial terms of the deal were not disclosed.